Borrow fee just jumped from 141.81% to 156.33% on Fintel. Available short shares also jumped from 3K to 65K. This is a good sign as it means shorts are trying to cover before the conference PR drops. Current Data for $BFRI: • Short Interest: 25.35% (ORTEX) • Borrow Fee: 156.33% (FINTEL), 317.65% (ORTEX) 🔥 • 65K short shares available • On the REG SHO Threshold list (30+ days in a row) • Market Utilization: 99.92% (Up from 84.72% last Monday) Long-term outlook on the Company: • Multiple Wallstreet Analysts rating of "Strong Buy" with target prices of $11, $15, and $20 • 2 FDA approved commercialized products • 3 ongoing product trials awaiting FDA Approval, 1 of which is for Basal Cell Carcinoma 🔥 • Presenting clinical data in 2 dermatology conferences this month; January 14th-19th & 24th-28th • Independent from former parent company (BFRA) as of 12/29/21, positioning it for potential buyout/merger by a larger pharmaceutical company. • 12 months of liquid CASH reserves.
1
3
3 Likes